| | | Ranibizumab N = 30,298 (%) | Aflibercept N = 4,689 (%) | Pegaptanib N = 525 (%) | Dexamethasone N = 5,303 (%) | Overall N = 40,815 (%) |
| | Sex | | | | | | | Female | 16,735 (55.2) | 2,594 (55.3) | 272 (51.8) | 2,442 (46.0) | 22,043 (54.0) | | Male | 13,563 (44.8) | 2,095 (44.7) | 253 (48.2) | 2,861 (54.0) | 18,772 (46.0) |
| | Age (years), median (IQR) | 73.7 (67.0–82.0) | 76.1 (71.0–83.0) | 78.0 (73.0–83.0) | 70.0 (63.0–78.0) | 73.5 (67.0–82.0) |
| | Age classes | | | | | | | <65 | 5,434 (17.9) | 518 (11.0) | 30 (5.7) | 1,462 (27.6) | 7,444 (18.2) | | 65–74 | 8,510 (28.1) | 1,201 (25.6) | 122 (23.2) | 1,745 (32.9) | 11,578 (28.4) | | 75–84 | 11,842 (39.1) | 2,116 (45.1) | 267 (50.9) | 1,699 (32.0) | 15,924 (39.0) | | ≥85 | 4,512 (14.9) | 854 (18.2) | 106 (20.2) | 397 (7.5) | 5,869 (14.4) |
| | Centre | | | | | | | Lombardy | 26,270 (86.7) | 3,790 (80.8) | 508 (96.8) | 4,776 (90.1) | 35,344 (86.6) | | Sicily | 3,100 (10.2) | 811 (17.3) | 10 (1.9) | 381 (7.2) | 4,302 (10.5) | | Calabria | 673 (2.2) | 80 (1.7) | 7 (1.3) | 124 (2.3) | 884 (2.2) | | Basilicata | 255 (0.8) | 8 (0.2) | — | 22 (0.4) | 285 (0.7) |
| | FU (years), median (Q1-Q3) | 2.6 (1.0–4.0) | 0.9 (0–2.0) | 4.3 (3.0–6.0) | 1.9 (1.0–3.0) | 2.3 (1.0–3.0) |
| | Comorbidities | | | | | | | Cardio- and cerebrovascular disease | | | | | | | Hypertension | 23,041 (76.0) | 3,717 (79.2) | 438 (83.4) | 4,046 (76.3) | 31,242 (76.5) | | Heart failure | 1,678 (5.5) | 299 (6.4) | 33 (6.3) | 344 (6.5) | 2,354 (5.8) | | Arrhythmias | 3,268 (10.8) | 619 (13.2) | 83 (15.8) | 545 (10.3) | 4,515 (11.1) | | Venous or arterial TE | 292 (1.0) | 44 (0.9) | 4 (0.8) | 51 (1.0) | 391 (1.0) | | Ischemic heart disease | 2,627 (8.7) | 439 (9.4) | 66 (12.6) | 535 (10.1) | 3,667 (9.0) | | Stroke and TIA | 4,208 (13.8) | 744 (15.8) | 124 (23.6) | 873 (16.4) | 6,029 (14.7) |
| | Metabolic disease | | | | | | | Dyslipidemia | 13,410 (44.3) | 2,133 (45.5) | 236 (45.0) | 2,352 (44.4) | 18,131 (44.4) | | Diabetes mellitus | 9,918 (32.7) | 1,160 (24.7) | 101 (19.2) | 1,688 (31.8) | 12,867 (31.5) |
| | Neurodegenerative disorders | | | | | | | Parkinson’s disease | 686 (2.3) | 148 (3.2) | 15 (2.9) | 122 (2.3) | 971 (2.4) | | Dementia | 207 (0.7) | 35 (0.7) | 4 (0.8) | 24 (0.5) | 270 (0.7) |
| | Other diseases | | | | | | | CKD | 768 (2.5) | 133 (2.8) | 16 (3.0) | 207 (3.9) | 1124 (2.8) | | COPD | 576 (1.9) | 194 (4.1) | 5 (1.0) | 102 (1.9) | 877 (2.1) | | Glaucoma | 1,767 (5.8) | 205 (4.4) | 30 (5.7) | 283 (5.3) | 2,285 (5.6) | | Cancer | 5,581 (18.4) | 1,038 (22.1) | 86 (16.4) | 900 (17) | 7,605 (18.6) |
| | Comorbidities Charlson’s index | | | | | | | 0 | 16,271 (53.7) | 2,628 (56.0) | 304 (57.9) | 2,894 (54.6) | 22,097 (54.1) | | 1 | 1,739 (5.7) | 370 (7.9) | 67 (12.8) | 269 (5.1) | 2,445 (6.0) | | 2 | 1,823 (6.0) | 397 (8.5) | 37 (7.0) | 366 (6.9) | 2,623 (6.4) | | 3 | 6,027 (19.9) | 767 (16.4) | 71 (13.5) | 950 (17.9) | 7,815 (19.1) | | ≥4 | 4,438 (14.6) | 527 (11.2) | 46 (8.8) | 824 (15.5) | 5,835 (14.3) |
| | Number of drugs | | | | | | | 0 | 3,401 (11.2) | 559 (11.9) | 31 (5.9) | 561 (10.6) | 4,552 (11.2) | | 1–3 | 10,660 (35.2) | 1,609 (34.3) | 140 (26.7) | 1,932 (36.4) | 14,341 (35.1) | | 4–6 | 9,085 (30.0) | 1,435 (30.6) | 195 (37.1) | 1,555 (29.3) | 12,270 (30.1) | | >6 | 7,152 (23.6) | 1,086 (23.2) | 159 (30.3) | 1,255 (23.7) | 9,652 (23.6) |
|
|
